Drug Approval | January 19, 2024
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Subscribe To Our Newsletter & Stay Updated
